HUMAN cDNA SEQUENCE PATENTABILITY PUBLIC DISCUSSIONS
HUMAN cDNA SEQUENCE PATENTABILITY PUBLIC DISCUSSIONS may be promoted by NIH as a follow up to its formal decision to abandon all U.S. patent applications for gene fragments identified in NIH labs. In a Feb. 11 statement, NIH recognized that "although it is no longer pursuing patent applications relating to cDNA sequences, it is possible that others -- in academia or private industry -- are. NIH believes it would be useful to continue the public dialogue on this subject and would participate in or facilitate such discussions."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth